Compositions and methods for inducing or enhancing connective tissue repair

• US 9,180,089 B2
• Filed: 09/21/2010
• Issued: 11/10/2015
• Est. Priority Date: 09/23/2009
• Status: Active Grant

• Current Assignee: Glenpharma AB
• Original Assignee: Glenpharma AB
• Inventors: Buckley, Peter Byron, Phillips, Mark William, Messmer, Konrad
• Primary Examiner(s): Lankford, Blaine
• Assistant Examiner(s): BERKE-SCHLESSEL, DAVID W
• Application Number:
  US13/496,933
• Publication Number:
  US 20120177600A1
• Time in Patent Office: 1,876 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/7016 Disaccharides, e.g. lactose, lactulose lactobionic acid A61K31/7032
• CPC Class Codes: A61K 31/715 Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• CPC Class Codes: A61K 31/721 Dextrans
• CPC Class Codes: A61K 31/728 Hyaluronic acid
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/08 Solutions composition of solutions A61K47/00
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A composition capable of attenuating platelet hyperactivation and associated methods for administering the same to a subject, the composition comprising an aqueous solution containing from about 0.1% to about 7.0% by weight of a glycosaminoglycan and from about 1.0% to about 32% by weight of a neutral polysaccharide.

Claims

1. A composition capable of synergistically attenuating platelet hyperactivation and enhancing connective tissue regeneration comprising:

a glycosaminoglycan with a weight average molecular weight from about 1.5 to about 6000 kD, and a concentration of about 0.1% to about 7.0%;

a neutral colloidal polysaccharide with a weight average molecular weight of about 20 to about 75 kD, and a concentration of about 1.0% to about 25%;

an isomaltose oligomer with a weight average molecular weight of about 0.4 to about 8 kD, and a concentration of about 0.3% to about 25%;

wherein the composition is an aqueous parenteral solution.

2. The composition of claim 1, wherein the glycosaminoglycan is selected from at least one of hyaluronan, chondroitin, dermatin, keratin, heparan, heparin, and GAG analogues dextran sulfate, pentosan sulfate, and wherein the neutral colloidal polysaccharide is selected from at least one of dextran, a hydroxyethyl starch and fucoidan.

3. The composition of claim 1, wherein the glycosaminoglycan is hyaluronan, and the neutral colloidal polysaccharide is dextran.

4. The composition of claim 1, wherein the glycosaminoglycan is a partially cross-linked hyaluronan having a degree of cross-linking that is less than about 25%.

5. The composition of claim 1, further comprising at least one of an antioxidant, a scavenger, a cytokine, a growth factor, an interleukin, a gene therapy agent, a viscoelastic agent and a stem cell.